40 Dalton Street,

Boston,

MA,

US,

ZIP: 02115

Phone:

FcRn, Fcγ, and IgG studies have been propelled by drug developers recently after Argenx’s potential FDA’s approval of first-in-class FcRn antagonist efgartigimod, AstraZeneca-Alexion’s $39 billion deal, and positive clinical updates from UCB’s Rozanolixizumab. Successful modulation of the Fc pathways and optimized IgG antibodies have proven clinical utility and demonstrate significant therapeutic potential with more players poised to bring their candidates through clinic.

The 2nd Fc Receptor & IgG Targeted Therapies Summit is the only dedicated meeting to bring you the most up-to-date with clinical and commercial developments on pioneering strategies to harness the full potential of FcRs.

This 3-day summit will return in 2022 with a fresh speaker line-up, 2 dedicated streams to offer you the A-Z of Fc receptors and IgG targeting. Bringing together exclusive data on targeting FcRn and FcyRs, and the engineering strategies employed to harness the FcR-IgG interaction to yield clinical efficacy. Hear from industry leaders such as FDA, Genentech, Alexion, UCB, Argenx, Genmab, and more as they modulate the dynamic behavior of IgG to fast-track candidates to address unmet medical needs.

Join 130+ experts in Boston to:
- Discuss translating novel Fc biology insights to innovative drug design
- Explore FcR antagonists, Fc fusion proteins, and novel antibodies
- Move confidently to clinic with predictive PKPD assessments from best-in-class cellular assays
- Enhance the therapeutic potential of antibodies with next-gen engineering strategies to minimize immunogenicity

Tickets    https://go.evvnt.com/972245-1?pid=1052
Brochure https://go.evvnt.com/972245-3?pid=1052

Prices:
Conference + 2 Workshops - Pharma Biotech USD 3897.00
Conference Only - Pharma Biotech USD 2999.00
Conference + 2 Workshops - Service provider USD 4697.00
Conference Only - Service provider USD 3599.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development

Basil Golding Director FDA/CBER, Hans de Haard Chief Scientific Officer Argenx, Fabian Kasermann Head of Preclinical Innovation CSL Behring, Stefan Zielonka Associate Director – Protein Engineering & Antibody Technologies Merck KGaA, David Humphreys Senior Director & Head of New Modality Therapeutics Protein Sciences UCB, Jennifer Dumont Senior Director Sanofi, Davide Corti Senior Vice President – Antibody Research Vir Bio, Peter Ulrichts Neuromuscular Franchise Scientist Argenx, Anthony Shock Director UCB, Dariush Mohammadyani Senior Scientist Janssen Pharmaceuticals, Karthik Viswanathan Director of Research Visterra, Alyson Smith Associate Director Cancer Target Discovery SeaGen, Rob de Jong Director – Antibody Research & Technology Genmab, Bram Estes Senior Scientist Amgen, Rolf Spring Deputy Head Preclinical Innovation CSL Behring, Jou-Ku Chung Head of Clinical Pharmacology & Translational Medicine Astria Therapeutics, Lu Shan Associate Director of Antibody Discovery & Engineering Denali Therapeutics, Chang Liu Associate Scientist Genentech, Julian Chandler Research Scientist III Alexion Pharmaceuticals, Eric Escobar Cabrera Cabrera Principal Scientist Zymeworks Inc, Brian Rabinovich Co-Founder & Chief Scientific Officer Fuse Biotherapeutics, Tilman Schlothauer Senior Principal Scientist, Matrix Lead Roche Innovation Center Roche Innovation Center, Martin Siegemund Senior Researcher Pieris, Sally Ward Director of Translational Immunology University of Southampton, Jan Terje Andersen Professor – Biomedical Innovation University of Oslo, Harald Kolmer Head of Department Technical University Darmstadt, Jeanette Leusen Head of Immunotherapy Lab University Medical Centre Utrecht, Kenneth Howard Associate Professor Interdisciplinary Nanoscience Center Aarhus University